Literature DB >> 28430373

A five-miRNA expression signature predicts survival in hepatocellular carcinoma.

Gang Liu1, Hui Wang1, Jin-Dong Fu2, Jing-Ying Liu2, Ai-Guo Yan1, Yan-Yan Guan1.   

Abstract

The aim of this study was to identify a microRNA (miRNA) expression signature for predicting HCC (hepatocellular carcinoma) survival. A total of 322 HCC patients in The Cancer Genome Atlas (TCGA) database were randomly divided into training and testing set. miRNAs, associated with survival time in the training set, were identified by using univariate Cox regression analysis. The risk score was formulated based on the expression levels of these miRNAs. Then the miRNA signature was validated in testing set through Kaplan-Meier analysis and log-rank test. hsa-miR-301a, hsa-miR-132, hsa-miR-212, hsa-miR-489, and hsa-miR-1468 were identified to formulate risk score in training set and used to calculate the risk score of each patients in testing set. About 161 patients in testing set were segregated into high- and low-risk group according to the median risk score. The survival time of high-risk group was significantly shorter (p = 0.0248) than low-risk group in testing test. The target genes of five miRNAs were significantly enriched in valine, leucine, and isoleucine degradation pathway and PPAR signaling pathway. hsa-miR-1468 had an up-regulated tendency in HCC tissues compared to adjacent tumor tissues. The expression of hsa-miR-301a, hsa-miR-132, hsa-miR-212, hsa-miR-489, and hsa-miR-1468, which might be potential biomarkers to evaluate HCC patients' prognosis.
© 2017 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  The Cancer Genome Altas database; hepatocellular carcinoma; microRNAs; prognosis

Mesh:

Substances:

Year:  2017        PMID: 28430373     DOI: 10.1111/apm.12697

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  12 in total

1.  Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.

Authors:  Ruba Al-Abdulla; Elisa Lozano; Rocio I R Macias; Maria J Monte; Oscar Briz; Colm J O'Rourke; Maria A Serrano; Jesus M Banales; Matias A Avila; Maria L Martinez-Chantar; Andreas Geier; Jesper B Andersen; Jose J G Marin
Journal:  Br J Pharmacol       Date:  2019-02-11       Impact factor: 8.739

2.  MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma.

Authors:  Zhikui Liu; Yufeng Wang; Changwei Dou; Liankang Sun; Qing Li; Liang Wang; Qiuran Xu; Wei Yang; Qingguang Liu; Kangsheng Tu
Journal:  J Exp Clin Cancer Res       Date:  2018-03-06

3.  Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.

Authors:  Elnaz Pashaei; Elham Pashaei; Maryam Ahmady; Mustafa Ozen; Nizamettin Aydin
Journal:  PLoS One       Date:  2017-06-26       Impact factor: 3.240

4.  A novel microRNA signature predicts survival in liver hepatocellular carcinoma after hepatectomy.

Authors:  Qiang Fu; Fan Yang; Tengxiao Xiang; Guoli Huai; Xingxing Yang; Liang Wei; Hongji Yang; Shaoping Deng
Journal:  Sci Rep       Date:  2018-05-21       Impact factor: 4.379

5.  Diagnostic and prognostic value of microRNA-628 for cancers.

Authors:  Jing-Hua Li; Shan-Shan Sun; Chang-Jin Fu; An-Qi Zhang; Chen Wang; Rong Xu; Shu-Yang Xie; Ping-Yu Wang
Journal:  J Cancer       Date:  2018-04-12       Impact factor: 4.207

6.  miR‑489 promotes apoptosis and inhibits invasiveness of glioma cells by targeting PAK5/RAF1 signaling pathways.

Authors:  Wei Wang; Luyang Zhang; Wei Gao; Dongyong Zhang; Zilong Zhao; Yijun Bao
Journal:  Oncol Rep       Date:  2019-10-22       Impact factor: 3.906

7.  Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma.

Authors:  Xiwen Liao; Guangzhi Zhu; Rui Huang; Chengkun Yang; Xiangkun Wang; Ketuan Huang; Tingdong Yu; Chuangye Han; Hao Su; Tao Peng
Journal:  Cancer Manag Res       Date:  2018-04-13       Impact factor: 3.989

8.  Identifying a miRNA signature for predicting the stage of breast cancer.

Authors:  Srinivasulu Yerukala Sathipati; Shinn-Ying Ho
Journal:  Sci Rep       Date:  2018-10-31       Impact factor: 4.379

9.  Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer.

Authors:  Yongmei Yang; Ailin Qu; Rui Zhao; Mengmeng Hua; Xin Zhang; Zhaogang Dong; Guixi Zheng; Hongwei Pan; Hongchun Wang; Xiaoyun Yang; Yi Zhang
Journal:  Mol Oncol       Date:  2018-10-10       Impact factor: 6.603

10.  A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of hepatocellular carcinoma.

Authors:  Fumao Bai; Huaibin Zhou; Mengni Ma; Chen Guan; Jianxin Lyu; Qing H Meng
Journal:  Mol Oncol       Date:  2018-05-21       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.